Income Before Tax
Pre-Tax Income
Royalty Pharma Pre-Tax Income increased by 31.6% to $468.26M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.8%, from $434.43M to $468.26M. Over 3 years (FY 2021 to FY 2025), Pre-Tax Income shows relatively stable performance with a 2.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Higher values indicate stronger overall profitability and operational efficiency before tax impacts.
Detailed definition
Measures the profitability of the company after all operating and non-operating expenses have been deducted, but before...
Peer comparison
A standard GAAP metric used universally to compare pre-tax performance across different industries.
Metric ID:
income_before_taxHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $806.76M | $221.80M | $53.67M | $128.08M | $491.60M | $220.41M | $509.09M | $351.34M | $122.08M | $717.59M | -$4.27M | $194.38M | $806.36M | $334.35M | $434.43M | $90.64M | $444.21M | $355.91M | $468.26M |
| QoQ Change | — | -72.5% | -75.8% | +138.6% | +283.8% | -55.2% | +131.0% | -31.0% | -65.3% | +487.8% | -100.6% | >999% | +314.8% | -58.5% | +29.9% | -79.1% | +390.1% | -19.9% | +31.6% |
| YoY Change | — | — | — | — | -39.1% | -0.6% | +297.5% | -28.5% | -44.6% | — | -100.8% | -44.7% | +560.5% | -53.4% | >999% | -53.4% | -44.9% | +6.4% | +7.8% |
Range-$4.27M – $806.76M
CAGR-11.4%
Avg YoY Growth+766.4%
Median YoY Growth-33.8%
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's pre-tax income?
- Royalty Pharma (RPRX) reported pre-tax income of $468.26M in Q1 2026.
- How has Royalty Pharma's pre-tax income changed year-over-year?
- Royalty Pharma's pre-tax income increased by 7.8% year-over-year, from $434.43M to $468.26M.
- What is the long-term trend for Royalty Pharma's pre-tax income?
- Over 3 years (2021 to 2025), Royalty Pharma's pre-tax income has grown at a 2.2% compound annual growth rate (CAGR), from $1.24B to $1.33B.
- What does pre-tax income mean?
- Total profit earned before accounting for income tax obligations.